Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT05451771

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Led by Rajshekhar Chakraborty, MD · Updated on 2025-07-08

53

Participants Needed

4

Research Sites

200 weeks

Total Duration

On this page

Sponsors

R

Rajshekhar Chakraborty, MD

Lead Sponsor

G

Genentech, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

CONDITIONS

Official Title

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at time of consent
  • Ability to comply with study protocol as judged by investigator
  • Confirmed systemic AL amyloidosis diagnosis by mass spectrometry or immunohistochemistry on tissue biopsy
  • Received at least one prior therapy including an anti-CD38 monoclonal antibody
  • Recovered from any transplant-related toxicities if history of autologous hematopoietic cell transplantation
  • Presence of t(11;14) detected by FISH at any time since diagnosis
  • Eastern Cooperative Oncology Group performance status of 0, 1, or 2
Not Eligible

You will not qualify if you...

  • Known allergy to any study drugs
  • History of other malignancy affecting study compliance or results (exceptions for certain cured cancers)
  • Clinically significant uncontrolled conditions including active infections
  • Currently on renal replacement therapy
  • Gastrointestinal disease or procedures affecting oral drug absorption
  • New York Heart Association Class III or IV heart failure
  • Mayo stage IIIB with NT-Pro BNP over 8500 pg/mL
  • Previous treatment with anti-apoptotic BCL-2 inhibitors
  • HIV not on antiretroviral therapy or active hepatitis A, B, or C infection
  • Symptomatic multiple myeloma meeting specific clinical criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Boston Medical Center

Boston, Massachusetts, United States, 02118

Actively Recruiting

2

Mayo Clinic Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

3

New York Presbyterian Hospital/Columbia University Irving Medical Center

New York, New York, United States, 10032

Actively Recruiting

4

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

R

Research Nurse Navigator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here